Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bardoxolone Blow-Up: Reata/Abbott CKD Drug Halted In Phase III

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Reata has terminated the Phase III BEACON trial for its chronic kidney disease hopeful bardoxolone methyl, partnered with Abbott, due to safety concerns.

You may also be interested in...



Reata Expands Options For Bardoxolone With New CKD Data

Once suspended due to safety issues, bardoxolone now has completed a Phase II study that showed kidney function benefit in four rare types of CKD. A pivotal study is underway, with another planned and more possible.

Outlook For Reata's Bardoxolone Improves With Phase II Updates

Latest data support moving bardoxolone into Phase III for autosomal dominant polycystic kidney disease (ADPKD).

An NME Surge After The Patent Cliff? Reinvention Of R&D Starts Paying Off In 2013 New Product Candidates

With more than 40 novel agents already pending at FDA, 2013 looks like a good bet to repeat the strong NME and novel biologic approval counts of 2012 and 2011. Big pharma and big markets dominate the 2013 slate so far, especially with diabetes, respiratory and central nervous system candidates.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS004977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel